USA flag logo/image

An Official Website of the United States Government

ANTITUMOR AND ANTI-HIV ACTIVITY OF A NOVEL INTERFERON

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
19076
Program Year/Program:
1992 / SBIR
Agency Tracking Number:
19076
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Peptech Inc
1 Progress Boulevard Box 26 Alachua, FL 32615
View profile »
Woman-Owned: No
Minority-Owned: Yes
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1992
Title: ANTITUMOR AND ANTI-HIV ACTIVITY OF A NOVEL INTERFERON
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

THE PHASE I OBJECTIVE IS TO ASSESS THE POTENTIAL FOR ANTITUMOR EFFECTS OF A NOVEL ALPHA INTERFERON (IFNALPHA), OVINE TROPHOBLAST PROTEIN-1 (OTP-1), AS WELL AS ITS ACTIVITY AGAINST HUMAN AND FELINE IMMUNODEFICIENCY VIRUS (HIV, FIV) INFECTIONS. SEVERAL CHARACTERISTICS OF OTP-1 MERIT ITS INVESTIGATION AS AN ANTITUMOR AGENT AND POTENTIALLY THERAPEUTIC FOR HUMAN AND FELINE AIDS. OTP-1 IS AS POTENT AN ANTIVIRAL AGENT AS ANY KNOW IFN, AND IMPORTANTLY, DISPLAYS ANTICELLULAR ACTIVITY IN THE ABSENCE OF TOXICITY. IT ACTS ON HUMAN CELLS BOTH IN ANTIVIRAL ASSAYS AND IN INHIBITION OF HIV REVERSE TRANSCRIPTASE ACTIVITY. OTP-1 IS AVAILABLE IN BOTH "NATURAL" AND RECOMBINANT FORMS IN LARGE QUANTITIES, AND THE FUNCTIONALLY IMPORTANT PORTIONS OF THE MOLECULE HAVE BEEN LOCALIZED ALLOWING FOR THE DEVELOPMENT OF AGONISTS AND ANTAGONISTS. WE WILL EMPLOY THE FOLLOWING SPECIFIC AIMS: (1) DETERMINE THE ANTINEOPLASTIC ACTIVITY OF OTP-1 IN VITRO AGAINST A PANEL OF TUMOR CELL LINES, (2) EXAMINE THE ANTIVIRAL ACTIVITY OF OTP-1 AND OTP-1 PEPTIDES RELATIVE TO OTHER IFNS IN HIV AND FIV INFECTION, (3) INCREASE THE THERAPEUTIC POTENTIAL OF OTP-1 BY EXAMINING RECOMBINANT OTP-1 AND HUMAN IFNALPHA CHIMERAS AND CONSTRUCTION OF OTP-1 MUTANTS WITH ENHANCED ACTIVITY AGAINST TUMOR CELLS AND HIV AND FIV INFECTIONS. SINCE IFN ALPHAS HAVE BEEN SHOWN TO BE EFFECTIVE ANTITUMOR AGENTS IN CLINICAL TRIALS AND OTP-1 HAS DEMONSTRATED POTENT ANTICELLULAR ACTIVITY WITHOUT TOXICITY, WE ANTICIPATE THAT OTP-1 WILL PROVE TO BE AN INVALUABLE TOOL IN ANTITUMOR THERAPY.

Principal Investigator:

Carol H Pontzer
9043926885

Business Contact:

Small Business Information at Submission:

Peptech Inc
1 Progress Boulevard Box 26 Alachua, FL 32615

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No